Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Crescent Biopharma, Inc.NASDAQ: CBIO
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 3269.4% from a year ago
Cash & equivalents stood at $189.16M at the end of Q1 FY2026, up 3269.4% from a year earlier and down 11.3% from the prior quarter. Over 3 fiscal years it compounded at +64.5% a year.
Context
- Cash & equivalents amounted to 95.0% of total assets at the end of Q1 FY2026, up 1.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +3269.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 213.19M USD
- Year-over-year change
- +513.2%
- 4-year CAGR
- +24.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 213.19M | +513.2% |
| FY2024 | 2024-12-31 | 34.77M | -16.8% |
| FY2023 | 2023-12-31 | 41.79M | -12.7% |
| FY2022 | 2022-12-31 | 47.87M | -47.0% |
| FY2021 | 2021-12-31 | 90.25M | — |
Cash & Equivalents vs competitors
How CBIO compares with its peers on the latest reported figures
- CBIO's Mar 2026 cash & equivalents of $189.16M is the highest of the 10 companies compared; the peer median is $54.53M.
- Its year-over-year change of +3269.4% is the highest of 10, against a peer median of -39.0%.
- Cash & equivalents amounts to 95.0% of total assets for CBIO, versus a peer median of 16.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $189.16M | +3269.4% | +64.5% | 95.0% | |
| Jun 2026 | $150M | -39.5% | +2.5% | 16.2% | |
| Sep 2026 | $100.46M | +55.0% | -53.2% | 8.5% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $55.17M | +34.4% | -4.3% | 26.9% | |
| Mar 2026 | $54.53M | -39.0% | +23.0% | 92.6% | |
NBPNovaBridge Biosciences | Dec 2025 | $30.11M | -94.0% | -78.9% | 80.8% |
| Mar 2026 | $28.83M | -39.4% | -59.7% | 8.0% | |
| Sep 2026 | $26.95M | -25.2% | -0.6% | 3.7% | |
| Mar 2026 | $12.44M | -14.7% | +101.6% | 8.5% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | $54.53M | -39.0% | -4.3% | 16.2% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 90.25M | 47.87M | 41.79M | 34.77M | 213.19M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.35K | 144.02K | 175.82K | 0 | 18M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 38K | 1.28M |
| Total Current Assets | 90.79M | 50.71M | 43.79M | 34.8M | 236.66M |
| Property, Plant & Equipment (Net) | 1.95M | 751.17K | 767.83K | 0 | 2.32M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 4.73M |
| Long-term Investments | 0 | 0 | 0 | 0 | 107K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.61M | 344.71K | 757.91K | 813K | (3.51M) |
| Total Non-current Assets | 3.56M | 1.1M | 1.53M | 813K | 3.64M |
| Total Assets | 94.35M | 51.81M | 45.32M | 35.62M | 240.29M |
| Account Payables | 2.11M | 970.19K | 868.12K | 107K | 10M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 4.16M |
| Other Current Liabilities | 2.5M | 2.97M | 2.96M | 76K | 16.36M |
| Total Current Liabilities | 11.82M | 8.88M | 6.84M | 9.61M | 36.07M |
| Long-term Debt | 0 | 0 | 0 | 37.48M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 4M | 0 |
| Total Non-current Liabilities | 918.61K | 0 | 66.84K | 41.48M | 1.21M |
| Total Liabilities | 12.74M | 8.88M | 6.9M | 51.1M | 37.28M |
| Common Stock | 52.31K | 54.38K | 64.39K | 1K | 28K |
| Retained Earnings | (372.9M) | (419.59M) | (456.49M) | (17.87M) | (171.81M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 81.6M | 42.93M | 38.41M | (15.48M) | 203.01M |
| Total Debt | 1.92M | 918.56K | 808.4K | 37.48M | 1.64M |
| Net Debt | (88.33M) | (46.95M) | (40.98M) | 2.72M | (211.55M) |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.